PURPOSE: LATIN is a multinational case-control study designed to identify risk factors for agranulocytosis and to estimate the incidence rate of the disease in some Latin American countries. METHODS: Each study site in Brazil, Argentina and Mexico conducted an active search of agranulocytosis patients in hematology clinics and looked for possible associations with drug use. RESULTS: The overall incidence rate was 0.38 cases per 1 million inhabitant-years. Agranulocytosis patients more often took medications already associated with agranulocytosis than controls (p = 0.01), mainly methimazole (OR 44.2, 95% CI 6.8 to infinity). The population attributable risk percentage (etiologic fraction) was 56%. The use of nutrient supplements was more frequent among patients than controls (p = 0.03). CONCLUSIONS: Agranulocytosis seems to be very rare in Latin America. The lower than expected number of cases identified during the study period precluded estimation of the risk associated to individual drugs, with the exception of methimazol. However, this is the longest series of agranulocytosis cases ever gathered in Latin America, and information on drug exposures was collected prospectively. The conclusion is that drug-induced agranulocytosis does not seem to be a major public health problem in the study regions.
PURPOSE: LATIN is a multinational case-control study designed to identify risk factors for agranulocytosis and to estimate the incidence rate of the disease in some Latin American countries. METHODS: Each study site in Brazil, Argentina and Mexico conducted an active search of agranulocytosispatients in hematology clinics and looked for possible associations with drug use. RESULTS: The overall incidence rate was 0.38 cases per 1 million inhabitant-years. Agranulocytosispatients more often took medications already associated with agranulocytosis than controls (p = 0.01), mainly methimazole (OR 44.2, 95% CI 6.8 to infinity). The population attributable risk percentage (etiologic fraction) was 56%. The use of nutrient supplements was more frequent among patients than controls (p = 0.03). CONCLUSIONS:Agranulocytosis seems to be very rare in Latin America. The lower than expected number of cases identified during the study period precluded estimation of the risk associated to individual drugs, with the exception of methimazol. However, this is the longest series of agranulocytosis cases ever gathered in Latin America, and information on drug exposures was collected prospectively. The conclusion is that drug-induced agranulocytosis does not seem to be a major public health problem in the study regions.
Authors: N Tavassoli; E Duchayne; B Sadaba; K Desboeuf; A Sommet; M Lapeyre-Mestre; M J Muoz; P Sie; J Honorato; J L Montastruc; H Bagheri Journal: Eur J Clin Pharmacol Date: 2007-01-17 Impact factor: 2.953
Authors: S Shapiro; S Issaragrisil; D W Kaufman; T Anderson; K Chansung; T Thamprasit; J Sirijirachai; A Piankijagum; Y Porapakkham; S Vannasaeng; P E Leaverton; N S Young Journal: Am J Trop Med Hyg Date: 1999-04 Impact factor: 2.345
Authors: Têmis Maria Félix; Bibiana Mello de Oliveira; Milena Artifon; Isabelle Carvalho; Filipe Andrade Bernardi; Ida V D Schwartz; Jonas A Saute; Victor E F Ferraz; Angelina X Acosta; Ney Boa Sorte; Domingos Alves Journal: Orphanet J Rare Dis Date: 2022-02-24 Impact factor: 4.123
Authors: Maira Isis S Stangler; João Pedro Neves Lubianca; Jaqueline Neves Lubianca; José Faibes Lubianca Neto Journal: Braz J Otorhinolaryngol Date: 2021-01-02